This archived news story is available only for your personal, non-commercial use. Information in the story may be outdated or superseded by additional information. Reading or replaying the story in its archived form does not constitute a republication of the story.
LEHI — Civica Rx, a nonprofit drug manufacturing company created by Intermountain Healthcare and others, has announced the first two drugs it will manufacture to offset the ongoing shortages affecting hospitals across the country.
Utah's Civica Rx, with Denmark-based Xellia Pharmaceuticals, will manufacture essential and commonly used antibiotics, including vancomycin and daptomycin, both injectables used to treat infections. Shortages of these, and more, are impacting patient care.
The Lehi-based company, established in 2018, has said it will work with various suppliers to deliver 14 essential generic medications this year to more than 900 hospitals.
"We thank Xellia for helping to lead the way in efforts to reduce chronic generic drug shortages in the United States, including treatments for serious infections caused by bacteria that are resistant to other antibiotics," said Martin VanTrieste, Civica president and CEO.
He said that by helping to stabilize the supply of vancomycin and daptomycin, "we will have a direct impact on patient safety and public health by providing consistent access to antibiotics that are important treatment options in the management of difficult-to-treat and life-threatening infections."
Xellia will make medications for Civica Rx under its Abbreviated New Drug Application and Civica will be responsible for proper labeling and dispensing, using the U.S. New Drug Code policy.